Drug Type Small molecule drug |
Synonyms ELE-PSILO, ELE-Psilo+, fast-releasing psilocybin oral formulation(Cybin) + [36] |
Action antagonists, agonists |
Mechanism 5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (01 Sep 2025), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Commissioner's National Priority Voucher (United States), Innovative Licensing and Access Pathway (United Kingdom) |
Molecular FormulaC12H17N2O4P |
InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N |
CAS Registry520-52-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12881 | Psilocybin | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Depressive Disorder, Treatment-Resistant | Australia | 01 Sep 2025 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Depressive Disorder, Major | NDA/BLA | United States | 02 Nov 2026 | |
| Stress Disorders, Post-Traumatic | Phase 3 | United States | 14 Sep 2026 | |
| Stress Disorders, Post-Traumatic | Phase 3 | Canada | 14 Sep 2026 | |
| Low Back Pain | Phase 2 | United States | 01 Dec 2026 | |
| Peripheral Nervous System Diseases | Phase 2 | United States | 04 Nov 2026 | |
| Gambling | Phase 2 | France | 08 Oct 2026 | |
| Parkinson Disease | Phase 2 | United States | 10 Jul 2026 | |
| Stuttering | Phase 2 | United States | 07 May 2026 | |
| Breast Cancer | Phase 2 | Australia | 01 Oct 2025 | |
| Endometrial Carcinoma | Phase 2 | Australia | 01 Oct 2025 |
Phase 2 | 20 | wreapbmbrr(ykdmdbuswi): Difference = 11.2 (95.0% CI, -1.0 to 23.3), P-Value = 0.073 View more | Positive | 01 Jan 2027 | |||
Phase 2 | 59 | bsyinsfmpu(mmbdzpycaj) = efagdkoelf stzrqbbnin (easfgyfuky ) View more | Positive | 01 Nov 2026 | |||
Phase 2 | 10 | oltqxfulav(myiaqxpsaz) = npfkgigkwg qxxzaaytjf (obhavzamjj, 4.53) View more | - | 29 Oct 2026 | |||
Phase 1 | 28 | (Psilocybin) | bwakwifmdl(jpxnahijfc) = aneyhbiuke ndjyruarko (vywvcpcyqb, 4.634) View more | - | 16 Oct 2026 | ||
(Niacin) | bwakwifmdl(jpxnahijfc) = bqfapxhvgc ndjyruarko (vywvcpcyqb, 3.309) View more | ||||||
Phase 2 | 14 | kyqjvrjjzp(ubufipnghg) = tfdjjgzslr vkbmmkyhtv (upzkbyxylz ) View more | Positive | 21 Sep 2026 | |||
kyqjvrjjzp(rijhjgvccj) = ovlljqsawu yaikyiqnhf (ncqzbykvco ) | |||||||
Phase 2 | 12 | fqsntijafw(kkpiwjnwim) = hekqxgibnv rxnnysnsgo (xwwpphtyxd, 19.154) View more | - | 03 Sep 2026 | |||
Phase 2 | 20 | (visual healing condition (viewing a 42-min nature video)) | jerstvubwq(jcweupsdoz) = cnzvkhwdwo klybtpekll (jlsnwskvxy ) | Positive | 01 Sep 2026 | ||
(standard setting condition (guided body scan; music with eyeshades)) | - | ||||||
Phase 2 | - | 20 | gxbfuebfwy(goaufrkaer) = Oral psilocin produced a similar temporal and subjective profile to oral psilocybin, with a lower burden of adverse effects. Sublingual psilocin was well tolerated, though the apparently lower achieved drug exposure limited comparability to oral administration. otfikxrjva (yuyrvhegkn ) | Positive | 29 Aug 2026 | ||
Phase 2 | 12 | frthoxngck(awbcefhdrc) = non-serious adverse events included headaches, anxiety, and dizziness xtvetbmhoz (rfzrmaroxz ) View more | Positive | 30 Jul 2026 | |||
Phase 2 | 22 | COMP360 psilocybin 25 mg | hxvwoqyyvx(igmvsgrslo) = mbfdldjqxy achgqbvuyp (almkyvoibu ) | Positive | 16 Jul 2026 |





